Jonathan Anderman
General Counsel bei COMPASS THERAPEUTICS, INC.
Aktive Positionen von Jonathan Anderman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| COMPASS THERAPEUTICS, INC. | General Counsel | 01.08.2021 | - |
| Unternehmenssekretär | 01.08.2021 | - |
Karriereverlauf von Jonathan Anderman
Ehemalige bekannte Positionen von Jonathan Anderman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01.01.2020 | 01.08.2021 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01.08.2015 | 01.08.2018 |
Ausbildung von Jonathan Anderman
| Boston University School of Law | Graduate Degree |
| The Pennsylvania State University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Corporate Officer/Principal | 2 |
| General Counsel | 1 |
| Corporate Secretary | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| COMPASS THERAPEUTICS, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- Jonathan Anderman
- Erfahrung